Scientists hunt genetic clues to predict leukemia treatment side effects
NCT ID NCT06580106
Summary
This study aims to understand how a person's genetic makeup influences the side effects they experience and how well they respond to a standard two-drug treatment for acute myeloid leukemia (AML). Researchers will enroll 50 adults newly diagnosed with AML who are receiving azacitidine and venetoclax as their standard care. They will collect cheek swabs for genetic analysis and measure drug levels in the blood to look for connections between genetics, side effects, and treatment outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27157, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.